DiastereoselectiVe Synthesis of Piperidine Imino Sugars
CHART 1
CHART 2
diabetes type 1, Gaucher disease, and lysosomal storage disorder,
and galacto-DNJ (AT1001) is currently in phase B clinical trials
for the treatment of Fabry’s disease.8 Conversely, other dias-
tereoisomers of DNJ have received less synthetic attention, and
therefore, there are few reports on glycosidase inhibition by allo-
DNJ (4),9 altro-DNJ (5),10,11 gulo-DNJ (6),12,13 ido-DNJ (7),14,15
and talo-DNJ (8,16,17 see Chart 2).18
bonium ion involved in glycoside hydrolysis and thus can act
as transition-state analogues for the competitive inhibition of
the glycosidases and glycosyltransferases. Inhibition of these
enzymes affects the maturation, transport, secretion, and function
of glycoproteins and could alter cell-cell or cell-virus recogni-
tion processes. Therefore, glycosidase inhibitors have been
shown to interact with receptors related to a wide range of
prominent diseases including viral infections, cancer, diabetes
and other metabolic disorders and are expected to find an
increasing number of applications as beneficial drugs.3
Inhibitors of glycosidases that are essential for survival, such
as the archetypal 1-deoxynojirimycin (DNJ, 1), manno-DNJ (2),
or galacto-DNJ (3), have been extensively studied in synthetic
chemical4-6 and biochemical laboratories (see Chart 1). Thus,
N-butyl-DNJ (Zavesca) and N-hydroxyethyl-DNJ (Miglitol or
Glyset)7 have been already approved for the treatment of
Although traditionally polyhydroxylated piperidines have
been synthesized through enantiospecific transformations of
(8) (a) Fan, J.-Q.; Ishii, S.; Asano, N.; Suzuki, Y. Nat. Med. 1999, 5,
(9) Previous synthesis of allo-DNJ: (a) Altenbach, H.-J.; Himmeldirk,
K. Tetrahedron: Asymmetry 1995, 6, 1077-1080. (b) Ikota, N.; Hirano,
J.-i.; Gamage, R.; Nakagawa, H.; Hama-Inaba, H. Heterocycles 1997, 46,
637-643. (c) Wu, X.-D.; Khim, S.-K.; Zhang, X.; Cederstrom, E.; Mariano,
P. S. J. Org. Chem. 1998, 63, 841-859. (d) Hong, B.-C.; Chen, Z.-Y.;
Nagarajan, A.; Kottani, R.; Chavan, V.; Chen, W.-H.; Jiang, Y.-F.; Zhang,
S.-C.; Liao, J.-H.; Sarshar, S. Carbohydr. Res. 2005, 340, 2457-2468. (e)
Ghosh, S.; Shashidhar, J.; Dutta, S. K. Tetrahedron Lett. 2006, 47, 6041-
6044. (f) Guaragna, A.; D’Errico, S.; D’Alonzo, D.; Pedatella, S.; Palumbo,
G. Org. Lett. 2007, 9, 3473-3476.
(10) For a carbohydrate-based synthesis of altro-DNJ, see ref 5f.
(11) Diastereoselective synthesis of altro-DNJ: (a) Xu, Y.-M.; Zhou,
W.-S. J. Chem. Soc., Perkin Trans. 1 1997, 741-746. (b) Kazmaier, U.;
Grandel, R. Eur. J. Org. Chem. 1998, 1833-1840. (c) Takahata, H.; Banba,
Y.; Sasatani, M.; Nemoto, H.; Kato, A.; Adachi, I. Tetrahedron 2004, 60,
8199-8205. (d) Dhavale, D. D.; Markad, S. D.; Karanjule, N. S.;
PrakashaReddy, J. J. Org. Chem. 2004, 69, 4760-4766; see also refs 6b,f,g
and 9f.
(3) (a) Asano, N. Glycobiology 2003, 13, 93R-104R. (b) Martin, O.
R., Compain, P., Eds.; Iminosugars: Recent Insights into their Bioactivity
and Potential as Therapeutic Agents. Curr. Top. Med. Chem. 2003, 3 (5).
(c) Watson, A. A.; Fleet, G. W. J.; Asano, N.; Molyneux, R. J.; Nash, R.
J. Phytochemistry 2001, 56, 265-295. (d) Iminosugars as Glycosidase
Inhibitors: Nojirimicyn and Beyond; Stu¨tz, A. E., Ed.; Wiley-VCH:
Weinheim, 1999.
(4) For recent reviews on the synthesis of polyhydroxylated piperidines
and other imino sugars, see: (a) Afarinkia, K.; Bahar, A. Tetrahedron:
Asymmetry 2005, 16, 1239-1287. (b) Pearson, M. S. M.; Mathe´-Allainmat,
M.; Fargeas, V.; Lebreton, J. Eur. J. Org. Chem. 2005, 2159-2191. (c)
Cipolla, L.; La Ferla, B.; Nicotra, F. Curr. Top. Med. Chem. 2003, 3, 485-
511.
(5) Enantiospecific (carbohydrate-based) synthesis of galacto-DNJ: (a)
Paulsen, H.; Hayauchi, Y.; Sinnwell, V. Chem. Ber. 1980, 113, 2601-
2608. (b) Legler, G.; Pohl, S. Carbohydr. Res. 1986, 155, 119-129. (c)
Bernotas, R. C.; Pezzone, M. A.; Ganem, B. Carbohydr. Res. 1987, 167,
305-311. (d) Furneaux, R.; Tyler, P. C.; Whitehouse, L. A. Tetrahedron
Lett. 1993, 34, 3609-3612. (e) Shilvock, J. P.; Fleet, G. W. J. Synlett 1998,
554-557. (f) Uriel, C.; Santoyo-Gonzalez, F. Synlett 1999, 593-595. (g)
McDonnell, C.; Cronin, L.; O’Brien, J. L.; Murphy, P. V. J. Org. Chem.
2004, 69, 3565-3568.
(6) Diastereoselective routes to galacto-DNJ: (a) Aoyagi, S.; Fujimaki,
S.; Yamazaki, N.; Kibayashi, C. J. Org. Chem. 1991, 56, 815-819. (b)
Liu, K. K.-C.; Kajimoto,T.; Chen, L.; Zhong, Z.; Ichikawa, Y.; Wong, C.-
H. J. Org. Chem. 1991, 56, 6280-6289. (c) Lees, W. J.; Whitesides, G.
M. Bioorg. Chem. 1992, 20, 173-179. (d) Chida, N.; Tanikawa, T.; Tobe,
T.; Ogawa, S. J. Chem. Soc., Chem. Commun. 1994, 1247-1248. (e)
Johnson, C. R.; Golebiowski, A.; Sundram, H.; Miller, M. W.; Dwaihy, R.
Tetrahedron Lett. 1995, 36, 653-654. (f) Asano, K.; Hakogi, T.; Iwama,
S.; Katsumura, S. Chem. Commun. 1999, 41-42. (g) Mehta, G.; Mohal,
N. Tetrahedron Lett. 2000, 41, 5741-5745. (h) Takahata, H.; Banba, Y.;
Ouchi, H.; Nemoto, H. Org. Lett. 2003, 5, 2527-2529. (i) Pyun, S.-j.; Lee,
K.-y.; Oh, C.-y.; Ham, W.-h. Heterocycles 2004, 62, 333-341.
(7) (a) Mitrakou, A.; Tountas, N.; Raptis, A. E.; Bauer, R. J.; Schulz,
H.; Raptis, S. A. Diabetic Med. 1998, 15, 657-660. (b) Cox, T.; Lachmann,
R.; Hollack, C.; Aerts, J.; van Weely, S.; Hrebicek, M.; Platt, F. M.; Butters,
T. D.; Dwek, R.; Moyses, C.; Gow, L.; Elstein, D.; Zimran, A. Lancet 2000,
355, 1481-1485. (c) Butters, T. D.; Dwek, R. A.; Platt, F. M. Curr. Top.
Med. Chem. 2003, 3, 561-574.
(12) Enantiospecific synthesis of gulo-DNJ: (a) Leontein, K.; Lindberg,
B.; Lo¨nngren, J. Acta Chem. Scand. B 1982, 36, 515-518. (b) Joseph, C.
C.; Regeling, H.; Zwanenburg, B.; Chittenden, G. J. F. Carbohydr. Res.
2002, 337, 1083-1087. See also ref 9e.
(13) Diastereoselective synthesis of gulo-DNJ: (a) Liao, L.-X.; Wang,
Z.-M.; Zhang, H.-X.; Zhou, W.-S. Tetrahedron: Asymmetry 1999, 10,
3649-3657. (b) Haukaas, M. H.; O’Doherty, G. A. Org. Lett. 2001, 3,
401-404. (c) Amat, M.; Huguet, M.; Llor, N.; Bassas, O.; Go´mez, A. M.;
Bosch, J.; Badia, J.; Baldoma, L.; Aguilar, J. Tetrahedron Lett. 2004, 45,
5355-5356. (d) Pyun, S.-J.; Lee, K.-Y.; Oh, C.-Y.; Joo, J.-E.; Cheon, S.-
H.; Ham, W.-H. Tetrahedron 2005, 61, 1413-1416; see also ref 6h.
(14) Enantiospecific synthesis of ido-DNJ: (a) Fowler, P. A.; Haines,
A. H.; Taylor, R. J. K.; Chrystal, E. J. T.; Gravestock, M. B. Carbohydr.
Res. 1993, 246, 377-381. (b) Le Merrer, Y.; Poitout, L.; Depezay, J.-C.;
Dosbaa, I.; Geoffroy, S.; Fogliettti, M.-J. Bioorg. Med. Chem. 1997, 5, 519-
533. (c) Hugel, H. M.; Hughes, A. B.; Khalil, K. Aust. J. Chem. 1998, 51,
1149-1155. (d) Lee, B. W.; Jeong, I.-Y.; Yang, M. S.; Choi, S. U.; Park,
K. H. Synthesis 2000, 1305-1309.
(15) Diastereoselective synthesis of ido-DNJ: (a) Dhavale, D. D.; Kumar,
K. S. A.; Chaudhain, V. D.; Sharma, T.; Sabharwal, S. G.; PrakashaReddy,
J. Org. Biomol. Chem. 2005, 3, 3720-3726. (b) Schaller, C.; Vogel, P.;
Ja¨ger, V. Carbohydr. Res. 1998, 314, 25-35. See also ref 6b,h.
(16) Carbohydrate-based synthesis of talo-DNJ: Hashimoto, H.; Hay-
akawa, M. Chem. Lett. 1989, 1881-1884. See also ref 12b.
(17) Diastereoselective synthesis of talo-DNJ: C. R. Johnson, Golebio-
wski, A.; Schoffers, E.; Sundram, H.; Braun, M. P. Synlett 1995, 313-
314. See also refs 6b,c and 13a.
(18) Kato, A.; Kato, N.; Kano, E.; Adachi, I.; Ikeda, K.; Yu, L.; Okamoto,
T.; Banba, Y.; Ouchi, H.; Takahata, H.; Asano, N. J. Med. Chem. 2005,
48, 2036-2044 and references therein.
J. Org. Chem, Vol. 73, No. 6, 2008 2241